Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

European journal of cancer (Oxford, England : 1990)·2012

Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.

Breast cancer research and treatment·2011

Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinoma.

The Journal of urology·2011

Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma.

Urology·2010

Incidence of road injuries in Mexico: country report.

International journal of injury control and safety promotion·2010

Microbiome oncolytic virus interactions in cancer: emerging evidence and therapeutic implications for immunotherapy.

Seminars in oncology·2026

Oncolytic viruses in gastrointestinal malignancies: Clinical progress, translational challenges, and future directions.

Seminars in oncology·2026

Bone metastasis in cancer: from microenvironmental remodeling to precision therapy.

Seminars in oncology·2026

Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab.

Seminars in oncology·2026

Rhabdomyolysis resulting from the interaction of rosuvastatin and abiraterone: A case study.

Seminars in oncology·2026

NK3 subsets are linked to NK cell exhaustion and immunotherapy responsiveness in tumor.

Seminars in oncology·2026

TREM2+ macrophages mediate anticancer therapy-induced immune evasion in lung adenocarcinoma via the CCL5/CCL22-Treg axis.

Frontiers in immunology·2026

Complications of clozapine cessation in the context of chemotherapy-related neutropenia-a case report.

Frontiers in oncology·2026

PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data.

Frontiers in immunology·2026

Network analysis of core symptom changes in hepatocellular carcinoma survivors after transarterial chemoembolization: A longitudinal study.

Frontiers in oncology·2026

Co-delivery of siPD-L1 and Tat-HSPB1 by G5PBA Enhances the Efficacy of Antitumor Therapy in Clear Cell Renal Cell Carcinoma.

Bioconjugate chemistry·2026

A Synergistic Approach Using a ROS-Responsive Lipid-Based Prodrug for Liposomal Delivery of Doxorubicin.

Bioconjugate chemistry·2026

Related Experiment Videos

Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer

Related Concept Videos

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.

Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinoma.

Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma.

Incidence of road injuries in Mexico: country report.

Microbiome oncolytic virus interactions in cancer: emerging evidence and therapeutic implications for immunotherapy.

Oncolytic viruses in gastrointestinal malignancies: Clinical progress, translational challenges, and future directions.

Bone metastasis in cancer: from microenvironmental remodeling to precision therapy.

Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab.

Rhabdomyolysis resulting from the interaction of rosuvastatin and abiraterone: A case study.

NK3 subsets are linked to NK cell exhaustion and immunotherapy responsiveness in tumor.

TREM2+ macrophages mediate anticancer therapy-induced immune evasion in lung adenocarcinoma via the CCL5/CCL22-Treg axis.

Complications of clozapine cessation in the context of chemotherapy-related neutropenia-a case report.

PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data.

Network analysis of core symptom changes in hepatocellular carcinoma survivors after transarterial chemoembolization: A longitudinal study.

Co-delivery of siPD-L1 and Tat-HSPB1 by G5PBA Enhances the Efficacy of Antitumor Therapy in Clear Cell Renal Cell Carcinoma.

A Synergistic Approach Using a ROS-Responsive Lipid-Based Prodrug for Liposomal Delivery of Doxorubicin.

Related Experiment Videos

Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer

Related Concept Videos

Related Articles